Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2023) 142 (Supplement 1): 619.

https://doi.org/10.1182/blood-2023-173225

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Blood (2023) 142 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2023-178304

Published: 2023

Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Blood (2023) 142 (Supplement 1): 446.

https://doi.org/10.1182/blood-2023-182792

Published: 2023

Journal Articles

NK Cells Contribute to Therapeutic Effects of Type I Interferons in Polycythaemia Vera

Sabine Muth, Johanna Lossa, Tina Schnöder, Joschka Bartneck, Federico Marini, Frederic Ries, Nora Sophia Lindhauer, Matthias Klein, Tobias Bopp, Hansjörg Schild, Florian H Heidel, Hans Christian Probst, Markus P. Radsak

Blood (2023) 142 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2023-179094

Published: 2023

Journal Articles

Characterization of TREM-1 Signaling in Human Neutrophils By Kinome Array and RNA-Seq

Frederic Ries, Matthias Klein, Nora Sophia Lindhauer, Sophie Többen, Florian Heidel, Markus P. Radsak

Blood (2023) 142 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2023-178717

Published: 2023

Journal Articles

Neutrophil Functionalities in Patients with Paroxysmal Nocturnal Haemoglobinuria Are Not Affected By Complement C5- Inhibition

Nora Sophia Lindhauer, Cornelia Sabine Schmidt, Frederic Ries, Eva-Marie Fehr, Markus P. Radsak, Florian Heidel

Blood (2023) 142 (Supplement 1): 5646.

https://doi.org/10.1182/blood-2023-187076

Published: 2023

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

Blood (2021) 138 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2021-150361

Published: 2021

Journal Articles

Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry

Blood (2021) 138 (Supplement 1): 1130.

https://doi.org/10.1182/blood-2021-153630

Published: 2021

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Blood (2018) 132 (Supplement 1): 563.

https://doi.org/10.1182/blood-2018-99-110439

Published: 2018

Journal Articles

CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis

Daniel Teschner, MD, Anna Cholaszczyńska, Frederic Ries, Hendrik Beckert, Matthias Theobald, Stephan Grabbe, MD, Markus P. Radsak, MD, Matthias Bros, PhD

Blood (2018) 132 (Supplement 1): 3690.

https://doi.org/10.1182/blood-2018-99-111843

Published: 2018

Journal Articles

Idelalisib Impairs TREM-1 Mediated Neutrophil Inflammatory Responses

Astrid Alflen, Nicole Stadler, Pamela Aranda Lopez, PhD, Daniel Teschner, MD, Georg Hess, Matthias Theobald, MD PhD, Markus P. Radsak, MD

Blood (2017) 130 (Supplement 1): 3569.

https://doi.org/10.1182/blood.V130.Suppl_1.3569.3569

Published: 2017

Journal Articles

Ruxolitinib Inhibits Toll-like Receptor or GM-CSF, but Not TREM-1 Mediated Neutrophil Activation

Pamela Aranda Lopez, PhD, Astrid Alflen, MD, Nicole Stadler, Cornelia Schmidt, Thomas Kindler, MD, Matthias Theobald, MD PhD, Markus P. Radsak, MD

Blood (2017) 130 (Supplement 1): 4805.

https://doi.org/10.1182/blood.V130.Suppl_1.4805.4805

Published: 2017

Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD

Blood (2017) 130 (Supplement 1): 2982.

https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982

Published: 2017

Journal Articles

Neutrophil Recruitment Is Regulated By Adamts-13 in a Murine Model of Invasive Aspergillosis

Astrid Hasibeder, Steve Prüfer, Katharina Ebner, Sebastian Reuter, Pamela Stein, Inge Scharrer, Fumiaki Banno, Michael Stassen, Hansjörg Schild, Kerstin Jurk, Markus Bosmann, Markus P. Radsak

Blood (2015) 126 (23): 1010.

https://doi.org/10.1182/blood.V126.23.1010.1010

Published: 2015

Journal Articles

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Goetze, MD, Philipp Kiewe, MD, Karin Mayer, MD, Oliver Ottman, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 411.

https://doi.org/10.1182/blood.V124.21.411.411

Published: 2014

Journal Articles

Bone Marrow Derived Mesenchymal Cells Secrete Granulopoietic Cytokines upon Danger Signaling

Stefan Wirths, MD, Stefanie Bugl, PhD, Markus P. Radsak, MD, Melanie Märklin, PhD, Martin R. Müller, MD PhD, Lothar Kanz, MD, Hans-Georg Kopp, MD

Blood (2014) 124 (21): 4115.

https://doi.org/10.1182/blood.V124.21.4115.4115

Published: 2014

Journal Articles

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series

Uwe Platzbecker, MD, Giuseppe Avvisati, MD, Gerhard Ehninger, MD, Laura Cicconi, MD, Christian Thiede, MD, Felicetto Ferrara, MD, Sonia Maria Orlando, B.Sc., Marco Vignetti, MD, Giorgina Specchia, MD, Marco Sborgia, Eros Di Bona, MD, Massimo Breccia, MD, Elisa Cerqui, MD, Konstanze Döhner, MD, Walter Fiedler, MD, Marie von Lilienfeld-Toal, MD, Bernd Hertenstein, MD, Helmut R. Salih, MD, Mohammed Wattad, MD, Michael Lübbert, Christian H. Brandts, MD, Mathias Hänel, MD, Norbert Schmitz, MD, Hartmut Link, MDPhD, Mariadomenica Divona, B.Sc., Chiara Frairia, MD, Enrico Maria Pogliani, MD, Claudio Fozza, MD, Alfonso Maria D'Arco, MD, Nicola Di Renzo, MD, Agostino Cortelezzi, MD, Francesco Fabbiano, MD, Paola Fazi, MD, Johannes Kullmer, MD, Walter E. Aulitzky, MD, Stefan W. Krause, MD, Hans Salwender, MD, Kerstin Schäfer-Eckart, MD, Markus P. Radsak, MD, Arnold Ganser, Hartmut Döhner, MD, Sergio Amadori, MD, Franco Mandelli, MD, Richard F. Schlenk, MD, Francesco Lo-Coco, MD

Blood (2014) 124 (21): 12.

https://doi.org/10.1182/blood.V124.21.12.12

Published: 2014

NARROW

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

NK Cells Contribute to Therapeutic Effects of Type I Interferons in Polycythaemia Vera

Characterization of TREM-1 Signaling in Human Neutrophils By Kinome Array and RNA-Seq

Neutrophil Functionalities in Patients with Paroxysmal Nocturnal Haemoglobinuria Are Not Affected By Complement C5- Inhibition

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis

Idelalisib Impairs TREM-1 Mediated Neutrophil Inflammatory Responses

Ruxolitinib Inhibits Toll-like Receptor or GM-CSF, but Not TREM-1 Mediated Neutrophil Activation

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Neutrophil Recruitment Is Regulated By Adamts-13 in a Murine Model of Invasive Aspergillosis

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Bone Marrow Derived Mesenchymal Cells Secrete Granulopoietic Cytokines upon Danger Signaling

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only